mianserin has been researched along with Anxiety Disorders in 39 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Anxiety Disorders: Persistent and disabling ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We present a case of recurrent hypothermia in concordant monozygotic twins born to a mirtazapine treated mother." | 7.74 | Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy. ( Klinger, G; Merlob, P; Sokolover, N, 2008) |
| "Pancreatitis can be a rare but serious side-effect of Mirtazapine." | 7.74 | Mirtazapine associated with recurrent pancreatitis - a case report. ( Burke, J; Hussain, A, 2008) |
| "Mirtazapine treatment was also related to faster improvement of sleep, quality of sleep and improved alertness following awakening, as shown by statistically significant differences on the self-rating LSEQ at various time points." | 6.69 | Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. ( Agren, H; Behnke, K; Helsdingen, JT; Leinonen, E; Skarstein, J, 1999) |
| "This study aimed to compare the effectiveness of mirtazapine and imipramine on not only the distressing symptoms of cancer patients such as pain, nausea, vomiting, appetite loss, and sleep disturbances but also depressive and anxiety symptoms." | 5.13 | Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. ( Akbiyik, DI; Alkis, N; Cankurtaran, ES; Ozalp, E; Soygur, H; Turhan, L, 2008) |
| "Mirtazapine was administered to 10 patients with DSM-IV major depressive disorder and comorbid GAD in an 8-week open-label study." | 5.09 | Mirtazapine in major depression with comorbid generalized anxiety disorder. ( DeVane, CL; Freund, BV; Goodnick, PJ; Puig, A, 1999) |
| "The aim of this study was to conduct a naturalistic, open-label examination of the efficacy and tolerability of mirtazapine (a medication with both serotonergic and noradrenergic properties) in the treatment of associated symptoms of autism and other pervasive developmental disorders (PDDs)." | 5.09 | A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. ( Guenin, KD; Kohn, AE; McDougle, CJ; Posey, DJ; Swiezy, NB, 2001) |
| "We present a case of recurrent hypothermia in concordant monozygotic twins born to a mirtazapine treated mother." | 3.74 | Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy. ( Klinger, G; Merlob, P; Sokolover, N, 2008) |
| "Pancreatitis can be a rare but serious side-effect of Mirtazapine." | 3.74 | Mirtazapine associated with recurrent pancreatitis - a case report. ( Burke, J; Hussain, A, 2008) |
| "Most patients with major depressive disorder (MDD) report clinically significant sleep problems." | 2.80 | Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. ( Luther, JF; Rush, AJ; Sung, SC; Trivedi, MH; Wisniewski, SR, 2015) |
| "A total of 60 MDD patients with a score above 18 on the Hamilton Anxiety Rating Scale (HARS) were randomly assigned to 8 weeks of fixed dosing treatment with mirtazapine (15-30 mg/day) and paroxetine (10-20 mg/day)." | 2.76 | Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. ( Cho, HB; Jeong, HS; Jung, JY; Kim, J; Kim, JE; Kim, TS; Lyoo, IK; Shin, E; Yoon, SJ, 2011) |
| "Mirtazapine treatment was also related to faster improvement of sleep, quality of sleep and improved alertness following awakening, as shown by statistically significant differences on the self-rating LSEQ at various time points." | 2.69 | Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. ( Agren, H; Behnke, K; Helsdingen, JT; Leinonen, E; Skarstein, J, 1999) |
| "Mianserin was shown to be more effective than diazepam in treating symptoms of both depression and anxiety, with significantly more patients in the mianserin group reaching resolution of symptoms in the time period studied." | 2.65 | Management of mixed affective symptoms in primary care: a critical experiment. ( Ancill, RJ; Davey, A; Kennerson, A; Poyser, J, 1984) |
| "Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) with a novel mode of action that differs from other antidepressants that are currently available." | 2.40 | Efficacy of mirtazapine in clinically relevant subgroups of depressed patients. ( Nutt, DJ, 1998) |
| "Mirtazapine has intrinsic receptor-blocking properties (in particular, serotonin-2 [5-HT2] receptor blockade) that can be linked to an early relief of anxiety symptoms during the treatment." | 2.40 | Care of depressed patients with anxiety symptoms. ( Nutt, DJ, 1999) |
| "Mirtazapine is an antidepressant with mode of action different from other currently available antidepressants." | 2.40 | Mirtazapine: other indications. ( Falkai, P, 1999) |
| "One hundred sixty-five patients with cancer, consecutively admitted to the Oncology Division of San Camillo-Forlanini Hospital, were recruited to the study." | 1.33 | Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division. ( Biondi, M; Cairoli, F; Costantini, A; Ferrarese, G; Pasquini, M; Picardi, A; Sternberg, C, 2006) |
| " Our quantitative pharmaco-EEG and clinical trials clearly demonstrated the significant value of quantitative EEG in early screening of psychoactive drugs in order to predict their clinical values and effective dosage ranges." | 1.25 | New drug developments in the Netherlands. "Tetracyclic" psychotropic drugs. ( Dincmen, K; Egilmez, S; Itil, TM; Polvan, N; Sungerbey, K, 1974) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (20.51) | 18.7374 |
| 1990's | 10 (25.64) | 18.2507 |
| 2000's | 12 (30.77) | 29.6817 |
| 2010's | 8 (20.51) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Šakić, B | 1 |
| Greš, A | 1 |
| Gajić, Z | 1 |
| Sung, SC | 1 |
| Wisniewski, SR | 2 |
| Luther, JF | 1 |
| Trivedi, MH | 2 |
| Rush, AJ | 1 |
| Chou, WH | 1 |
| Lin, FS | 1 |
| Lin, CP | 1 |
| Lin, WY | 1 |
| Yie, JC | 1 |
| Sun, WZ | 1 |
| Sokolover, N | 1 |
| Merlob, P | 1 |
| Klinger, G | 1 |
| Khan, AY | 1 |
| Golewale, MH | 1 |
| Kahn, DA | 1 |
| Klein, DN | 1 |
| Arnow, BA | 1 |
| Barkin, JL | 1 |
| Dowling, F | 1 |
| Kocsis, JH | 1 |
| Leon, AC | 1 |
| Manber, R | 1 |
| Rothbaum, BO | 1 |
| Croom, KF | 1 |
| Perry, CM | 1 |
| Plosker, GL | 1 |
| Sukul, YR | 1 |
| Birkenhäger, TK | 1 |
| van den Broek, WW | 1 |
| Mulder, PG | 1 |
| Bruijn, JA | 1 |
| Schutters, SI | 2 |
| Van Megen, HJ | 2 |
| Van Veen, JF | 2 |
| Denys, DA | 1 |
| Westenberg, HG | 2 |
| Kim, JE | 1 |
| Yoon, SJ | 1 |
| Kim, J | 1 |
| Jung, JY | 1 |
| Jeong, HS | 1 |
| Cho, HB | 1 |
| Shin, E | 1 |
| Lyoo, IK | 1 |
| Kim, TS | 1 |
| Egashira, N | 1 |
| Shirakawa, A | 1 |
| Abe, M | 1 |
| Niki, T | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Oishi, R | 1 |
| Fujiwara, M | 1 |
| Estabrook, KR | 1 |
| Pheister, M | 1 |
| Lenze, EJ | 1 |
| Schruers, KR | 1 |
| Gambi, F | 1 |
| De Berardis, D | 1 |
| Campanella, D | 1 |
| Carano, A | 1 |
| Sepede, G | 1 |
| Salini, G | 1 |
| Mezzano, D | 1 |
| Cicconetti, A | 1 |
| Penna, L | 1 |
| Salerno, RM | 1 |
| Ferro, FM | 1 |
| Pasquini, M | 1 |
| Biondi, M | 1 |
| Costantini, A | 1 |
| Cairoli, F | 1 |
| Ferrarese, G | 1 |
| Picardi, A | 1 |
| Sternberg, C | 1 |
| Fusar-Poli, P | 1 |
| Matteo, L | 1 |
| Luca, de M | 1 |
| Politi, P | 1 |
| Cortesi, M | 1 |
| Carboni, V | 1 |
| Vaishnavi, S | 1 |
| Connor, K | 1 |
| Davidson, JR | 1 |
| Itil, TM | 1 |
| Polvan, N | 1 |
| Dincmen, K | 1 |
| Egilmez, S | 1 |
| Sungerbey, K | 1 |
| Hussain, A | 1 |
| Burke, J | 1 |
| Cankurtaran, ES | 1 |
| Ozalp, E | 1 |
| Soygur, H | 1 |
| Akbiyik, DI | 1 |
| Turhan, L | 1 |
| Alkis, N | 1 |
| Beaumont, G | 1 |
| Gringras, M | 1 |
| Ankier, SI | 1 |
| Ancill, RJ | 1 |
| Poyser, J | 1 |
| Davey, A | 1 |
| Kennerson, A | 1 |
| Bjertnaes, A | 1 |
| Block, JM | 1 |
| Hafstad, PE | 1 |
| Holte, M | 1 |
| Ottemo, I | 1 |
| Larsen, T | 1 |
| Pinder, RM | 2 |
| Steffensen, K | 1 |
| Stulemeijer, SM | 2 |
| Khan, MC | 1 |
| Bennie, EH | 1 |
| Ravens, MA | 1 |
| Ivanov, V | 1 |
| Popov, G | 1 |
| Delini-Stula, A | 1 |
| Mikkelsen, H | 1 |
| Angst, J | 1 |
| Nutt, DJ | 2 |
| Tabeeva, GR | 1 |
| Levin, IaI | 1 |
| Korotkova, SB | 1 |
| Khanunov, IG | 1 |
| Farah, A | 1 |
| Bech, P | 1 |
| Raabaek Olsen, L | 1 |
| Jarløv, N | 1 |
| Hammer, M | 1 |
| Schütze, T | 1 |
| Breum, L | 1 |
| Falkai, P | 1 |
| Goodnick, PJ | 1 |
| Puig, A | 1 |
| DeVane, CL | 1 |
| Freund, BV | 1 |
| Leinonen, E | 1 |
| Skarstein, J | 1 |
| Behnke, K | 1 |
| Agren, H | 1 |
| Helsdingen, JT | 1 |
| Posey, DJ | 1 |
| Guenin, KD | 1 |
| Kohn, AE | 1 |
| Swiezy, NB | 1 |
| McDougle, CJ | 1 |
| Kuniyoshi, M | 1 |
| Arikawa, K | 1 |
| Miura, C | 1 |
| Inanaga, K | 1 |
| Brandon, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Blended Stepped-care Mental Well-being Intervention for Adults: A Randomized Controlled Trial[NCT05395312] | 402 participants (Anticipated) | Interventional | 2022-07-30 | Active, not recruiting | |||
| Cortical rTMS as a Treatment for Depression[NCT05487911] | 50 participants (Anticipated) | Interventional | 2023-06-14 | Enrolling by invitation | |||
| Functional Connectivity Alterations in Suicidal Patients Among Opioid Users[NCT05489042] | 80 participants (Anticipated) | Interventional | 2022-01-04 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for mianserin and Anxiety Disorders
| Article | Year |
|---|---|
Mirtazapine: a review of its use in major depression and other psychiatric disorders.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Databases, Bibliographic; Depressive Disorder, | 2009 |
Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Anxiety Disorders; Benzamides; Clinical Trials as | 1995 |
Efficacy of mirtazapine in clinically relevant subgroups of depressed patients.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials a | 1998 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Mirtazapine: other indications.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials as Topic; Depressive Dis | 1999 |
14 trials available for mianserin and Anxiety Disorders
| Article | Year |
|---|---|
Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Citalopram; Comorbidit | 2015 |
Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Double-Blind Method; F | 2010 |
Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxie | 2011 |
Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo.
Topics: Adrenergic alpha-Antagonists; Adult; Anxiety Disorders; Double-Blind Method; Drug Therapy, Combinati | 2011 |
Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Appetite; Constipation; Female; Humans; | 2005 |
Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine.
Topics: Adaptation, Psychological; Adjustment Disorders; Adrenergic alpha-Antagonists; Adult; Antidepressive | 2008 |
Trazodone and mianserin in general practice.
Topics: Adult; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder; Dibenzazepines; Double-Blin | 1984 |
Management of mixed affective symptoms in primary care: a critical experiment.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder; Diazepam; | 1984 |
A multicentre placebo-controlled trial comparing the efficacy of mianserin and chlordiazepoxide in general practice patients with primary anxiety.
Topics: Adolescent; Adult; Anxiety Disorders; Chlordiazepoxide; Clinical Trials as Topic; Dibenzazepines; Do | 1982 |
Mianserin and doxepin in the treatment of outpatient depression with anxiety.
Topics: Adult; Aged; Anxiety Disorders; Depressive Disorder; Dibenzazepines; Doxepin; Electrocardiography; F | 1983 |
Relief of SSRI-induced sexual dysfunction with mirtazapine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Drug Therapy, Combination; Female; Fluox | 1999 |
Mirtazapine in major depression with comorbid generalized anxiety disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Comorbidity; Depressive Disorder; Drug A | 1999 |
Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders | 1999 |
A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
Topics: Adolescent; Adult; Aggression; Antidepressive Agents, Tricyclic; Anxiety Disorders; Appetite; Autist | 2001 |
20 other studies available for mianserin and Anxiety Disorders
| Article | Year |
|---|---|
Mirtazapine-Induced Hyponatremia in a Patient with Systemic Mastocytosis and Generalized Anxiety Disorder.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Humans; Hyponatremia; Mastocytosis, Systemic; M | 2023 |
Mirtazapine, in orodispersible form, for patients with preoperative psychological distress: A pilot study.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Disorder; Female; Human | 2016 |
Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Body Temperature Regulation; Female; Fol | 2008 |
A case of chronic drug-induced neutropenia.
Topics: Anti-Anxiety Agents; Anti-Infective Agents; Anxiety Disorders; Chronic Disease; Female; Humans; Metr | 2008 |
Early adversity in chronic depression: clinical correlates and response to pharmacotherapy.
Topics: Adolescent; Adult; Age of Onset; Aged; Algorithms; Antidepressive Agents; Anxiety Disorders; Bupropi | 2009 |
Trait anxiety and defensive functioning in relation to antidepressant treatment outcome.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Female; Huma | 2009 |
N-acetyl-L-cysteine inhibits marble-burying behavior in mice.
Topics: Acetylcysteine; alpha-Tocopherol; Animals; Antipsychotic Agents; Anxiety Disorders; Behavior, Animal | 2012 |
A case of quetiapine XR and divalproex-associated neutropenia followed by successful use of ziprasidone.
Topics: Adult; Anti-Anxiety Agents; Antimanic Agents; Antipsychotic Agents; Anxiety Disorders; Bipolar Disor | 2012 |
Reversal of SSRI-associated urinary retention with mirtazapine augmentation.
Topics: Adrenergic alpha-Antagonists; Adult; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety | 2012 |
Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Citalopram; Depressive D | 2006 |
Anxiety and depression after lung transplantation: Mirtazapine as a first-choice agent?
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Disorder; Drug Interactions; Humans; | 2007 |
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials.
Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disord | 2007 |
New drug developments in the Netherlands. "Tetracyclic" psychotropic drugs.
Topics: Adjustment Disorders; Anxiety Disorders; Bipolar Disorder; Brain; Clinical Trials as Topic; Dibenzox | 1974 |
Mirtazapine associated with recurrent pancreatitis - a case report.
Topics: Abdominal Pain; Adult; Amylases; Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Dis | 2008 |
[Comparative results of the treatment of anxiety in the depressive syndrome with Tolvon, Vivalan and Alival].
Topics: Aged; Anxiety Disorders; Depressive Disorder; Dibenzazepines; Humans; Isoquinolines; Mianserin; Midd | 1981 |
The pharmacologic rationale for the clinical use of antidepressants.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder; | 1997 |
[Treatment of fibromyalgia].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Second-Generation; Anxiety Di | 1998 |
A case of sequential anti-stress medication in a patient with major depression resistant to amine-reuptake inhibitors.
Topics: Amines; Antidepressive Agents; Anxiety Disorders; Dehydroepiandrosterone; Depressive Disorder, Major | 1999 |
Panic anxiety after abrupt discontinuation of mianserin.
Topics: Adult; Anxiety Disorders; Depressive Disorder; Fear; Female; Humans; Mianserin; Panic; Substance Wit | 1989 |
Management of depression in general practice.
Topics: Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Family Practice; Humans; Mianserin; P | 1986 |